drugset / Trial / NCT04697056
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
Timeline
- Start
- 2021-01-25
- Primary completion
- 2021-11-19
- Completion
- 2021-11-19
Outcome
Outcome not reported
Stopped: “Administrative Reason”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imsidolimab | Monoclonal antibody | 200 mg | Subcutaneous |